Table 4 Comparison of baseline characteristics between the CS less than 7.5 mg/day group and not
Variables | CS ≦ 7.5 mg at year 1 (n = 21) | Not (n = 21) | *P value |
|---|---|---|---|
Male, n (%) | 6/21 (28.6%) | 9/21 (42.9) | 0.5204 |
Age (years) | 42.8 ± 13.6 | 33.1 ± 10.5 | 0.0166* |
Disease duration (entero-BD, months) | 42.4 ± 68.8 | 40.3 ± 26.2 | 0.1341 |
Multiple ulceration, n (%) | 4/21 (19.1%) | 10/21 (47.6%) | 0.1001 |
History of relapse, n (%) | 11/21 (52.4%) | 13/21 (61.9%) | 0.7557 |
History of perforation, n (%) | 3/21 (14.3%) | 3/21 (14.3%) | 1.0000 |
History of surgery, n (%) | 4/21 (19.1%) | 3/21 (14.3%) | 1.0000 |
Concomitant CS dose (mg/day) | 22.7 ± 21.5 | 28.9 ± 17.1 | 0.1450 |
Concomitant colchicine use, n (%) | 15/21 (71.4%) | 10/21 (47.6%) | 0.2082 |
Concomitant drug use, n (%) (MTX, MS/SSZ, AZ) | 18/21 (85.7%) | 15/21 (71.4%) | 0.4537 |
Concomitant MTX use, n (%) | 15/21 (71.4%) | 3/21 (14.3%) | 0.0004* |
TNF-i use, n (%) | 17/21 (81.0%) | 3/21 (14.3%) | < 0.0001* |
DAIBD | 70.0 ± 40.5 | 86.7 ± 25.3 | 0.0570 |